COCP · Cocrystal Pharma, Inc. · Metrics
$1.12
-0.03 (-2.42%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.96M
Shares
19.26M
Volume · Oct 5
41.31K
Avg daily vol (3M)
55.34K
COCP metrics
54 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$1.15
Market cap
$21.96M
Price action
20 metricsPrice change (1W)
-2.1%
Price change (30D)
-3.0%
Price change (3M)
+10.1%
Price change (6M)
-24.2%
Price change (YTD)
+16.8%
Price change (1Y)
-6.1%
Trailing year
Price change (5Y)
—
52-week high
$1.57
52-week low
$0.82
Change from 52-week high
-27.1%
Change from 52-week low
+39.6%
Annualized volatility
76.6%
Annualized volatility (3M)
56.6%
Beta
1.7
RSI (14D)
49.3
Price vs SMA 50
+3.9%
Price vs SMA 200
+3.8%
Avg volume (3M)
55,343
Relative volume
0.3
Average dollar volume
$59,758
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
19.26M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
21.0
reciprocal yield 4.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-45.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-476.0%
Trailing 12 months
Net margin
-479.0%
Gross profit (TTM)
$4.09M
Operating profit (TTM)
−$10.11M
Net income (TTM)
−$9.94M
Trailing 12 months
Diluted EPS (TTM)
$-0.75
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-69.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+35.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-951.9%
Return on assets
-213.8%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
−$10.06M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$7.03M
Total assets
$4.65M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$7.95M
Capital expenditures (TTM)
$8,000
R&D (TTM)
$6.09M
SG&A (TTM)
—
Stock compensation (TTM)
$280,000
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
28
13F filer change QoQ
+2
Institutional ownership
5.8%
Short interest
3 metricsShort interest
1.7%
Latest settlement · 6.4 days to cover
Days to cover
6.4d
Short-squeeze score
60 / 100
Insider activity
2 metricsNet insider buying (90D)
$80,406
Insider-sentiment score
82 / 100
Risk flags
1 metricsGoing concern
Flagged